Clinical remission in severe asthma: lights and shadows on an ambitious goal
C Pelaia, E Zannoni, G Paoletti, V Marzio… - Current Opinion in …, 2024 - journals.lww.com
Asthma is a common respiratory condition that affects more than 300 million people globally.
It has variable symptoms and severity levels, with about 10% of patients experiencing …
It has variable symptoms and severity levels, with about 10% of patients experiencing …
The Role of Galectins in Asthma Pathophysiology: A Comprehensive Review
A Portacci, I Iorillo, L Maselli, M Amendolara… - Current Issues in …, 2024 - mdpi.com
Galectins are a group of β-galactoside-binding proteins with several roles in immune
response, cellular adhesion, and inflammation development. Current evidence suggest that …
response, cellular adhesion, and inflammation development. Current evidence suggest that …
Type-2 severe asthma comorbidities in the era of biologics: time to rethink clinical response?
A Portacci, S Dragonieri… - Expert Review of …, 2024 - Taylor & Francis
Introduction The use of monoclonal antibodies in patients with severe asthma has led
clinicians to explore new levels of clinical improvement, as testified by the growing interest …
clinicians to explore new levels of clinical improvement, as testified by the growing interest …